Panel Gives Mixed Reviews To Using Single Trial For Community-Acquired Pneumonia

The Anti-Infective Drugs Advisory Committee's failure to agree on a preferred approval pathway for antibiotics to treat community-acquired bacterial pneumonia opens the door for FDA to offer several options to industry.